2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Computational Biology, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Gene Therapy, Non-Biological Therapies, Women’s Health, Adverse Events, Artificial Intelligence (AI), Biological Processes, Pathogenesis, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Viral, Bacterial, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2936 Social vulnerability index and care patterns among adults with sickle cell disease: A nationwide epic cosmos analysis

Priyanshi Maurya, MBBS, Varshini Srinivasan, MBBS2, Vishnu Sudhakaran, MD3, Ayesha Laraib, MBBS4, Sukul Khanna5, Sawsan El sweilmein, MD6, Kamalpreet Singh Walia, MBBS7, Vasu Bansal8, Simran Chandra9
1 University of Missouri - Kansas City, Kansas City, Missouri, United States
2 University of Missouri - Kansas City, Kansas City, Missouri, United States
3 University of Missouri - Kansas City, Kansas City, Missouri, United States
4 University of Missouri - Kansas City, Kansas City, Missouri, United States
5 University of Missouri - Kansas City, Kansas City, Missouri, United States
6 University of Missouri - Kansas City, Kansas City, Missouri, United States
7 Creighton University, Omaha, United States
8 University of Missouri - Kansas City, Kansas City, Missouri, United States
9 University of Missouri - Kansas City, Kansas City, Missouri, United States

Introduction: Sickle cell disease (SCD) is associated with high acute care utilization and variable receipt of hydroxyurea, transfusion, and vaccination. Neighborhood-level social vulnerability may relate to these care patterns but has not been examined at national scale in a large electronic health record dataset. We evaluated the association between the CDC Social Vulnerability Index (SVI) and four domains of SCD care using a nationwide electronic health record dataset.

Methods: We conducted a retrospective descriptive analysis using Epic Cosmos, a de-identified dataset of 5,357,246 encounters across 50 states. Encounters between January 1, 2010 and January 1, 2026 among adults ≥18 years with a diagnosis of SCD were included, and sickle cell trait diagnosis was excluded. Encounters were linked to census tract-level SVI and stratified into quartiles (Q1 = lowest vulnerability, Q4 = highest). The denominator for all measures was the total number of qualifying encounters. Measures were: (1) encounters admitted with sickle cell crisis as the admitting diagnosis; (2) encounters at which hydroxyurea was listed as a prescription medication; (3) encounters with exchange transfusion following a diagnosis of SCD; and (4) encounters at which meningococcal or pneumococcal vaccine was documented at any point after the first SCD-associated encounter within the study period. Proportions were compared across quartiles using the chi-square test, and ordered trend across quartiles was assessed using the Cochran-Armitage test. 

Results: A total of 5,357,246 encounters of adults with SCD met inclusion criteria. 588,706 encounters (11%) occurred among patients in Q1, 883,200 encounters (16.4%) in Q2, 1,397,159 encounters in Q3 and 2,488,181 (46.45%) in Q4. Mean age was 27 years, and 57% of encounters were among female patients. Sickle cell crisis was the admitting diagnosis in 27.61% of Q1, 29.91% of Q2, 30.96% of Q3, and 32.38% of Q4 encounters (p<0.001; p-trend<0.001). Hydroxyurea was listed as a prescription medication at 6.94%, 6.40%, 6.39%, and 6.59% of encounters across Q1-Q4 (p<0.001; p-trend<0.001). Exchange transfusion occurred at 0.08%, 0.13%, 0.18%, and 0.17% of encounters (p<0.001; p-trend<0.001). Meningococcal or pneumococcal vaccine administration was documented at 44.02%, 42.71%, 41.83%, and 41.13% of encounters (p<0.001; p-trend<0.001). A monotonic graded relationship across quartiles was observed for sickle cell crisis admissions (+4.77 percentage points from Q1 to Q4) and, inversely, for vaccine administration (−2.89 percentage points). Hydroxyurea documentation varied by 0.35 percentage points without a consistent gradient, and exchange transfusion increased from Q1 through Q3 without further increase in Q4.

Conclusions: In this descriptive nationwide analysis of 5,357,246 encounters for adults with SCD, nearly half occurred among patients residing in the highest-vulnerability neighborhoods. Encounters in higher-vulnerability quartiles were more frequently admitted for sickle cell crisis and less frequently accompanied by documented meningococcal or pneumococcal vaccination, while hydroxyurea documentation and exchange transfusion did not differ across quartiles. 

Priyanshi Maurya, MBBS: No relevant conflicts of interest to declare.